Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials by Weinblatt, M, Taylor, P, Burmester, G, Saifan, C, Walls, C, Issa, M, Rooney, T, Takeuchi, T

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis by Weinblatt, M, Taylor, P, Burmester, G, Witt, S, Saifan, C, Walls, C, Rooney, T, Chen, L, Takeuchi, T

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis by Taylor, P, Blanco, R, Ikeda, K, Jia, B, Chen, YF, Walls, C, Haladyj, E, Fautrel, B

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy by Taylor, P, Alten, R, Álvaro-Gracia, JM, Kaneko, Y, Walls, C, Quebe, A, Jia, B, Bello, N, Terres, JR, Fleischmann, RM

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study by Smolen, JS, Xie, L, Jia, B, Taylor, PC, Burmester, G, Tanaka, Y, Elias, A, Cardoso, A, Ortmann, R, Walls, C, Dougados, M

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study by Smolen, JS, Xie, L, Jia, B, Taylor, PC, Burmester, G, Tanaka, Y, Elias, A, Cardoso, A, Ortmann, R, Walls, C, Dougados, M

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis by Taylor, P, Weinblatt, M, Burmester, G, Rooney, T, Witt, S, Walls, C, Issa, M, Salinas, C, Saifan, C, Zhang, X, Cardoso, A, Gonzalez-Gay, M, Takeuchi, T